238 related articles for article (PubMed ID: 31493711)
1. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg.
Alexa-Stratulat T; Pešić M; Gašparović AČ; Trougakos IP; Riganti C
Drug Resist Updat; 2019 Sep; 46():100643. PubMed ID: 31493711
[TBL] [Abstract][Full Text] [Related]
2. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR).
Lee CH
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):43-52. PubMed ID: 14754411
[TBL] [Abstract][Full Text] [Related]
3. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets.
Kopecka J; Trouillas P; Gašparović AČ; Gazzano E; Assaraf YG; Riganti C
Drug Resist Updat; 2020 Mar; 49():100670. PubMed ID: 31846838
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
6. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
7. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS
Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma.
Naito S; Yokomizo A; Koga H
Int J Urol; 1999 Sep; 6(9):427-39. PubMed ID: 10510888
[TBL] [Abstract][Full Text] [Related]
9. Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux.
Willers C; Svitina H; Rossouw MJ; Swanepoel RA; Hamman JH; Gouws C
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1949-1976. PubMed ID: 31292714
[TBL] [Abstract][Full Text] [Related]
10. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.
Chen Z; Shi T; Zhang L; Zhu P; Deng M; Huang C; Hu T; Jiang L; Li J
Cancer Lett; 2016 Jan; 370(1):153-64. PubMed ID: 26499806
[TBL] [Abstract][Full Text] [Related]
11. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
Mohammad IS; He W; Yin L
Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
[TBL] [Abstract][Full Text] [Related]
12. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
13. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
15. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
16. Relevance of multidrug resistance in the age of targeted therapy.
Türk D; Szakács G
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
[TBL] [Abstract][Full Text] [Related]
17. Non-P-glycoprotein drug export mechanisms of multidrug resistance.
List AF
Semin Hematol; 1997 Oct; 34(4 Suppl 5):20-4. PubMed ID: 9408957
[TBL] [Abstract][Full Text] [Related]
18. Zinc finger proteins and ATP-binding cassette transporter-dependent multidrug resistance.
Barzegar S; Pirouzpanah S
Eur J Clin Invest; 2024 Feb; 54(2):e14120. PubMed ID: 37930002
[TBL] [Abstract][Full Text] [Related]
19. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
[TBL] [Abstract][Full Text] [Related]
20. Transporter-mediated multidrug resistance and its modulation by Chinese medicines and other herbal products.
Wang Z; Ravula R; Cao M; Chow M; Huang Y
Curr Drug Discov Technol; 2010 Mar; 7(1):54-66. PubMed ID: 20156136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
